

Tuesday, February 11 2020

The Market Herald
 FIRST WITH THE NEWS THAT MOVES MARKETS



Home ASX News ASX 200 Day Trading Leaders Industry Sectors



on app **PM1** Pure Minerals (ASX:PM1) acquires Sewa Bay Nickel **COH** Cochlear (ASX:COH) hears an earnings reduction after coronavirus sweep **ALC** Alcidion Group (ASX)

Holista Colltech (ASX:HCT) raises \$800,000 after extending CPA

ASX:HCT MCAP \$32.81M



Ashleigh Melanko
 Markets Reporter
 ashleigh.melanko@themarket Herald.com.au
 11 February 2020 13:15



- Following the extension of its Controlled Placement Agreement (CPA) with Acuity Capital, Holista Colltech (HCT) has raised \$800,000
- The biotech company used the CPA to issue 6.5 million of its shares at an issue price of 12.3 cents
- Both companies have agreed to increase the amount of capital available under the CPA by \$2 million
- Holista has gained a lot of traction over the past month while its NatShield hand sanitiser is used as protection against the coronavirus
- Company shares have spiked 10.7 per cent today, with shares currently trading for 15.5 cents apiece

Following the extension of its Controlled Placement Agreement (CPA) with Acuity Capital, Holista Colltech (HCT) has raised \$800,000.

The company has used the CPA to issue 6.5 million of its shares at an issue price of 12.3 cents to raise the money.

This price represents a 4.7 per cent discount to the 15-day volume-weighted average price (VWAP) up to and including February 10, 2020.

Both Holista and Acuity have agreed to increase the amount of capital available under the CPA by an additional \$2 million.

This increases the total amount available under the CPA by \$2 million.

As a guarantee for the CPA, Holista has agreed to issue a further 5.5 million shares at no cost to Acuity.

However, Holista may, at any time, cancel the CPA and buy back the collateral shares for no cost, but this is subject to shareholder approval.

Headquartered in Perth, Holista is a research-driven biotechnology company that delivers first-class natural ingredients and wellness products globally.

It's considered a leader in wellness research, studying the efficacy of herbs and ingredients in creating healthier food.

Holista has gained a lot of traction over the past month while its NatShield hand sanitiser is used as protection against the coronavirus.

Just [yesterday](#), the company responded to further demand for its NatShield sanitising spray.

Holista will now ship 90,000 units of the product to Kuala Lumpur after the original 60,000 bottles sold out within weeks. The company has now received orders for 107,000 units.

NatShield contains a plant-based active ingredient, Path-Away which is proven to kill over 170 pathogens.

The product harnesses active organic substances which cripple a virus' cell walls which cause bacteria to group together and destroy themselves within seconds.

The company also has an anti-viral [nasal balm](#) which contains the same properties as NatShield.

According to Holista, nose protection is the most effective method of keeping viruses out of the body.

While the nasal balm isn't available as of yet, Holista is speeding up development and said that a patent will be filed as early as the end of March 2020 with the product to be available by the end of July if all goes according to plan.

Holista's share price has spiked 10.7 per cent with shares trading for 15.5 cents apiece at 2:13 pm AEDT.